MedPath

Phase II Study of Carboplatin +Docetaxel +Bevacizumab in Chemo-Naive Patients with stage IIIB and IV Non-Squamous Non-Small-Cell Lung Cancer

Phase 2
Conditions
Chemo-Naive Patients with stage IIIB and IV Non-Squamous Non-Small-Cell Lung Cancer
Registration Number
JPRN-UMIN000004524
Lead Sponsor
The Tokyo cooperative oncology group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1)uncontrolled infection or serious medical complications 2)massive,pleural effusion or ascites (accept controllable pleural effusion with OK-432) 3)untreated current brain metastasis 4)severe cardiac disease 5)uncontrollable hypertension 6)receiving anticoagulant drug(except Aspirin under 325mg/day) 7)current or previous histoty ofhemoptysis(2.5ml)due to NSCLC 8)history of hemoptysis(over 1week)or receive oral/i.v. hemostatic drug 9)cavity in tumor 10with great vessel invasion 11)uncontrolled hypertension 12)current or previous(within the last 1 year)history of GI perforation 13)history of myocardial infarction and cerebral infarction 14)interstitial pneumonia or pulmonary fibrosis detectable on CT scan 15)history of drug induced interstitial pneumonia 16)The operation has been scheduled for the examination period 17)history of active double cancer within 5 years 18)history of active psychological disease 19)history of pregnancy or lactation 20)Patients whose participation in the trial is judged to be inappropriate by the attending doctor

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath